Morphine News and Research RSS Feed - Morphine News and Research

Morphine is an extremely potent opiate analgesic psychoactive drug and is considered to be the prototypical opioid. In clinical medicine, morphine is regarded as the gold standard, or benchmark, of analgesics used to relieve severe or agonizing pain and suffering.
Public health advisories reduce rate of codeine dispensed to postpartum women

Public health advisories reduce rate of codeine dispensed to postpartum women

Public health advisories from the U.S. Food and Drug Administration (FDA) and Health Canada were associated with significant reductions in the rate of dispensing of codeine to postpartum women, according to a study in the May 12 issue of JAMA. [More]
Scripps Florida scientists win $2.4 million to expand development of new pain therapies

Scripps Florida scientists win $2.4 million to expand development of new pain therapies

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.4 million from the National Institute on Drug Abuse of The National Institutes of Health to expand development of new pain medications with fewer side effects than those currently available... [More]
Egalet announces business highlights, financial results for first quarter 2015

Egalet announces business highlights, financial results for first quarter 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today reported business highlights and financial results for the three months ended March 31, 2015. [More]
Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers. [More]
Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's. [More]
Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Pacira Pharmaceuticals, Inc. today announced data demonstrating the benefits associated with the use of EXPAREL (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patients. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Mesenchymal stem cell transplantation reduces opioid tolerance, opioid-induced pain

Mesenchymal stem cell transplantation reduces opioid tolerance, opioid-induced pain

Mesenchymal stem cell (MSC) transplantation reduced opioid tolerance and opioid-induced hyperalgesia caused by daily morphine injections in rats, according to new research. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
New compound appears to play role in development of opioid tolerance

New compound appears to play role in development of opioid tolerance

While opioids are a widely used treatment for pain, patients who take them on a regular basis can become tolerant, requiring a higher dose for continued pain relief. In a study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, researchers identified a compound that appears to play a role in the development of opioid tolerance. [More]
Increasing opioid doses to manage chronic pain may intensify depression

Increasing opioid doses to manage chronic pain may intensify depression

Patients who increased doses of opioid medicines to manage chronic pain were more likely to experience an increase in depression, according to Saint Louis University findings in Pain. [More]
FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine. [More]
New compound may lead to development of potential therapeutics for neuropathic pain

New compound may lead to development of potential therapeutics for neuropathic pain

A new compound discovered by a team of UC Davis investigators has potent actions against production of a chemical that which is implicated in the development of chronic pain following a peripheral nerve injury in the spinal cord. [More]
New multidisciplinary approach to managing colorectal operation results in shorter hospital stays, lower costs

New multidisciplinary approach to managing colorectal operation results in shorter hospital stays, lower costs

A new multidisciplinary approach to managing patients undergoing a colorectal operation results in shorter hospital stays, fewer complications, and lower medical costs, according to research results published online in the Journal of the American College of Surgeons. [More]
Study could lead to potential drug treatment for fighting addiction

Study could lead to potential drug treatment for fighting addiction

A research team led by the University of Colorado Boulder has discovered a mechanism in the brain that is key to making cocaine seem pleasurable, a finding that could lead to a drug treatment for fighting addiction. [More]
Preliminary research supports alternative drug for treating neonatal abstinence syndrome

Preliminary research supports alternative drug for treating neonatal abstinence syndrome

In the past decade, the number of Kentucky babies starting life with a drug dependency, or neonatal abstinence syndrome (NAS), has skyrocketed from 1.3 per 1,000 births to 19 per 1,000 births. [More]
Morphine after tonsillectomy may be life threatening for children

Morphine after tonsillectomy may be life threatening for children

Treating post-operative pain with morphine can cause life-threatening respiratory problems in some children who have had their tonsils and/or adenoids removed, new research has found. [More]
Childbearing women who take painkillers may face increased risk of birth defects

Childbearing women who take painkillers may face increased risk of birth defects

More than one-fourth of privately-insured and one-third of Medicaid-enrolled women of childbearing age filled prescriptions for opioid-based (narcotic) painkillers between 2008 and 2012, according to a new analysis published today by the U.S. Centers for Disease Control and Prevention in its Morbidity and Mortality Weekly Report (MMWR). [More]
Use of methadone drug to treat pain increases mortality risk

Use of methadone drug to treat pain increases mortality risk

Outside the hospital, use of methadone to treat pain carries a 46 percent increased risk of death when compared to the equally effective but more costly alternative, morphine SR (sustained release). [More]
Advertisement
Advertisement